Bibliografía del artículo
1. Hay R, Baran R. Onychomycosis: a proposed revisión of the clinical classification. J Am Acad Dermatol 65:1219-1227, 2011.
2. Baran R, Faergemann J, Hay RJ. Superficial white onychomycosis-a síndrome with different fungal causes and paths of infection. J Am Acad Dermatol 57:879-882, 2007.
3. Dompmartin D, Dompmartin A, Deluol AM, Grosshans E, Coulaud JP. Onychomycosis and AIDS. Int J Dermatol 29:337-339, 1990.
4. Moreno Coutiño G, Arenas R, Reyes Terán G. Improvement of onychomycosis after initiation of combined antiretroviral therapy. Int J Dermatol 52:311-313, 2013.
5. Gómez Moyano E, Crespo Erchiga V. HIV infection manifesting as proximal White onychomycosis. N Engl J Med 377(18):e26, 2017.
6. Daniel III CR, Norton LA, Scher RK. The spectrum of nail disease in patients with human immunodeficiency virus. J Am Acad Dermatol 27:93-97, 1992.
7. Ruiz López P, Moreno Coutiño G, Fernández Martínez R, Espinoza Hernández J, Rodríguez Zulueta P, Reyes Terán G. Evaluation of improvement of onychomycosis in HIV infected patients after initiation of combined antiretroviral therapy without antifungal treatment. Mycoses 58:516-521, 2015.
8. Jiménez González C, Mata Marín JA, Arroyo Anduiza CI, Ascencio Montiel IJ, Fuentes Allen JL, Gaytán Martínez J. Prevalence and etiology of onychomycosis in the HIV infected population. Eur J Dermatol 23:378-81, 2013.
9. Moreno Coutiño G, Reyes Terán G. Dermatosis en pacientes con VIH/sida en el Centro de Investigación de Enfermedades Infecciosas. Salud Pública Mex 57:486-487, 2015.
10. Vasudevan B, Sagar A, Bahal A, Mohanty AP. Cutaneous manifestations of HIV. A detailed study of morphological variants, markers of advanced disease, and the changing spectrum. MJMAFI 68:20-27, 2012.
11. Sánchez Moreno EC, Marioni Manríquez S, Fernández Martínez RF, Moreno Coutiño G. Accelerated nail growth rate in HIV patients. Int J Dermatol 56:524-526, 2017.
12. Sunny N, Nair SP, Justus L, Beena A. Total dystrophic onychomycosis caused by Talaromyces marneffei in a patient with acquired immunodeficiency síndrome on combined anti-retroviral therapy. Indian J Dermatol Venereol Leprol 84:87-90, 2018.
13. Kaplan MH, Sadick N, McNutt S, Meltzer M, Sarngadharan, Pahwa S. Dermatologic findings and manifestations of acquired immunodeficiency síndrome (AIDS). J Am Acad Dermatol 16:485-506, 1987.
14. Velásquez Agudelo V, Cardona Arias JA. Meta-analysis of the utility of culture, biopsy, and direct KOH examination for the diagnosis of onychomycosis. BMC Infect Dis 17:166, 2017.
15. Jeelani S, Ahmed QM, Lanker AM, Hassan I, Jeelani N, Fazili T. Histopathological examination of nail clippings using PAS staining (HPE-PAS): gold standard in diagnosis of onychomycosis. Mycoses 58:27-32, 2015.
16. Hajar T, Fernández Martínez R, Moreno Coutiño G, Vásquez del Mercado E, Arenas R. Modified PAS stain: A new diagnostic method for onychomycosis. Rev Iberoam Micol 33:34-37, 2016.
17. Mayer E, Izhak OB, Bergman R. Histopathological periodic acid-schiff stains of nail clippings as a second-line diagnostic tool in onychomycosis. Am J Dermatopathol 34:270-273, 2012.
18. Nagar R, Nayak CS, Deshpande S, Gadkari RP, Shastri J. Subungual hyperkeratosis nail biopsy: a better diagnostic tool for onychomycosis. India J Dermatol Venereol Leprol 78:620-624, 2012.
19. Ghannoum M, Mukherjee P, Isham N, Markinson B, Del Rosso J, Leal Luis. Examining the importance of laboratory and diagnostc testing when treating and diagnosing onychomycosis. Int J Dermatol 57:131-138, 2018.
20. Nargis T, Pinto M, Shenoy MM, Hedge S. Dermoscopic features of distal lateral subungual onychomycosis. Indian Dermatol Online J 9:16-19, 2018.
21. Bet DL, Dos Reis AL, Di Chiacchio N, Belda Jr W. Dermoscopy and onychomycosis: guided nail abrasión for mycological samples. An Bras Dermatol 90:904-906, 2015.
22. Riahi RR, Cohen PR, Goldberg LH. Subungual amelanotic melanoma masquerading as onychomycosis. Cureus 10(3):e2307, 2018.
23. Lubis NZ, Muis K, Nasution LH. Polymerase chain reaction-restriction fragment length polymorphism as a confirmatory test for onychomycosis. Open Access Maced J Med Sci 14:280-283, 2018.
24. Snell M, Klebert M, Önen N, Hubert S. A novel treatment for onychomycosis in people living with HIV infection: Vicks VapoRub™ is effective and safe. J Assoc Nurses AIDS Care 27:109-113, 2016.
25. Zhang L, Xu H, Shj Y, Tao Y, Li X. An exploration of the optimum dosage and number of cycles of itraconazole pulse therapy for severe onychomycosis. Mycoses 2018. doi: 10.1111/myc.12799. [Epub ahead of print].
26. Kreijkamp-Kaspers S, Hawke KL, Van Driel ML. Oral medications to treat toenail fungal infection. JAMA 319:397-398, 2018.
27. Rizi K, Mohammed IK, Xu K, Kinloch AJ, Charalambides MN, Murdan S. A systemic approach to the formulation of anti-onychomycotic nail patches. Eur J Pharm Biopharm 127:355-365, 2018.
28. Park KY, Suh JH, Kim BJ, Kim MN, Hong CK. Randomized clinical trial to evaluate the efficacy and safety of combination therapy with short pulsed 1,064 nm neodinium-doped yttrium aluminium garnet laser and amorolfine nail lacquer for onychomycosis. Ann Dermatol 29:699-705, 2017.
29. Veiga FF, Gadelha MC, Da Silva MRT, Costa MI, Kischkel B, De Castro Hoshino LV, Sato F, Baessi ML, Voideleski MF, Vascincellos Pontello V, Vicente VA, Bruschi ML, Negri M, Svidzinki TIE. Propolis exrtract for onychomycosis topical treatment: from bench to clinic. Front Microbiol 25(9):779, 2018.